Cytomegalovirus proctitis as a complication of COVID-19 with immunosuppressive treatments.

Autor:	Maillet F; Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France., Pourbaix A; Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France., le Pluart D; Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France., Sirmai L; Hepatogastroenterology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France., Postolache SA; Pathology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France., Couvelard A; Pathology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France., Houhou-Fidouh N; Virology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France., Males L; Radiology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France., Deconinck L; Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France., Lescure FX; Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France.
Jazyk:	angličtina
Zdroj:	IDCases [IDCases] 2021; Vol. 24, pp. e01111. Date of Electronic Publication: 2021 Apr 05.
DOI:	10.1016/j.idcr.2021.e01111
Abstrakt:	We report a case of reactivated biopsy-proven cytomegalovirus proctitis complicating the course of severe COVID-19 pneumonia treated with dexamethasone, anakinra and lopinavir/ritonavir. No other contributing factor was found than iatrogenic immunosuppression and COVID-19 immune dysregulation. We draw attention to the immunosuppressive risk when treating severe COVID-19 pneumonia with immunomodulators. Competing Interests: All authors declare they do not have any competing interest regarding this work. (© 2021 Published by Elsevier Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu